Få tillgång till
till ratingen av Finrange-aktier
till ratingen av Finrange-aktier
Med denna tariff kommer du att kunna använda tjänsten utan begränsningar, all information kommer att vara tillgänglig
Betyg Finrange
Uppkommande händelser Rallybio Corp
Alla evenemang
Inga kommande evenemang planerade
Sammanfattande analys Rallybio Corp
Få tillgång till
till ratingen av Finrange-aktier
till ratingen av Finrange-aktier
Med denna tariff kommer du att kunna använda tjänsten utan begränsningar, all information kommer att vara tillgänglig
Intäkter och nettointäkter Rallybio Corp
Alla parametrar
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Adress:
234 Church Street, New Haven, CT, United States, 06510
